Protagonist Therapeutics (PTGX) stock surged 7.57% in pre-market trading on Monday, fueled by a reiterated Buy rating from BMO Capital analyst Etzer Darout. The analyst cited the company's promising pipeline and strategic partnerships as key growth drivers.
Darout expressed optimism about Protagonist's pipeline and collaborations, noting their potential to drive significant shareholder value in the coming years. The positive analyst coverage boosted investor sentiment, pushing the stock higher ahead of the market open.
Additionally, HC Wainwright maintained its Buy rating on Protagonist Therapeutics, reflecting sustained positive analyst sentiment toward the company's prospects. Investors will be closely watching for further developments from Protagonist's pipeline and partnership efforts.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.